Immunome, Inc.

Equities

IMNM

US45257U1088

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:38:41 2024-05-06 pm EDT			5-day change	1st Jan Change
15.38 ^USD	-2.38%		+10.71%	+42.99%

May. 02	Immunome, Inc. Appoints Kinney Horn as Chief Business Officer	CI
Apr. 30	JPMorgan Starts Immunome With Overweight Rating, $24 Price Target	MT

Immunome, Inc. Announces Promotion of Max Rosett to Executive Vice President, Operations

February 01, 2024 at 06:12 am EST

On January 31, 2024, the Board of Directors of Immunome, Inc. promoted Max Rosett, the Company?s Senior Vice President, Operations and Interim Chief Financial Officer to Executive Vice President, Operations and Interim Chief Financial Officer.

Latest news about Immunome, Inc.

Immunome, Inc. Appoints Kinney Horn as Chief Business Officer	May. 02	CI
JPMorgan Starts Immunome With Overweight Rating, $24 Price Target	Apr. 30	MT
Immunome, Inc. Appoints Sandra M. Swain to Board of Directors	Apr. 25	CI
Guggenheim Starts Immunome With Buy Rating, $35 Price Target	Apr. 15	MT
Wedbush Adjusts Immunome's Price Target to $33 From $27, Maintains Outperform Rating	Apr. 01	MT
Immunome, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Immunome, Inc. completed the acquisition of Assets from Ayala Pharmaceuticals, Inc..	Mar. 24	CI
Immunome Closes $230 Million Public Offering	Feb. 16	MT
Immunome Prices Stock Offering at $20 a Share	Feb. 14	MT
Wedbush Raises Immunome's PT to $27 From $19 on Heels of Announced Plans to Acquire AL101, AL102 From Ayala Pharmaceuticals; Keeps Outperform Rating	Feb. 07	MT
Sector Update: Health Care Stocks Gain Late Afternoon	Feb. 06	MT
Top Midday Gainers	Feb. 06	MT
Immunome to Acquire Potential Desmoid Tumor Treatment From Ayala Pharmaceuticals; Shares Climb	Feb. 06	MT
Immunome, Inc. entered into a definitive asset purchase agreement to acquire Assets from Ayala Pharmaceuticals, Inc. for $94.2 million.	Feb. 05	CI
Immunome, Inc. Announces Promotion of Max Rosett to Executive Vice President, Operations	Feb. 01	CI
Wedbush Raises Immunome's PT to $19 From $12 After Acquiring IM-1021 From Zentalis Pharmaceuticals, Maintains Outperform Rating	Jan. 23	MT
Immunome, Inc. and Zentalis Pharmaceuticals, Inc. Enter into an Exclusive, Worldwide License Agreement Under Which Immunome Has Licensed from Zentalis ZPC-21, A Preclinical Ror1 Antibody-Drug Conjugate	Jan. 08	CI
Immunome Appoints Phil Roberts as Chief Technical Officer	Jan. 04	MT
Immunome Appoints Phil Roberts as Chief Technical Officer	Jan. 04	CI
Immunome, Inc. Announces Board Changes	Jan. 02	CI
Immunome, Inc. Announces Executive Changes, Effective January 2, 2024	Dec. 29	CI
Immunome, Inc. Announces Chief Financial Officer Changes, Effective January 2, 2024	Dec. 29	CI
Immunome Signs Asset Purchase Agreement for Acquisition of Antibody-Related Assets From Atreca	Dec. 26	MT
Immunome, Inc. entered into an agreement to acquire Substantially all Assets of Atreca, Inc. for $12.5 million.	Dec. 25	CI
Immunome Shares Rise After Wedbush Starts Coverage With outperform Rating	Dec. 19	MT

Chart Immunome, Inc.

Duration

Period

More charts

Company Profile

Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. The Company's portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its programs include Oncology (IMM-ONC-01), LU FAP, and SARS-CoV-2 (IMM-BCP-01). The oncology program is an antibody (IMM-ONC-01) against interleukin-38 (IL-38) a novel immune modulator for the treatment of various solid tumors. Its Targeted Effector platform uses small molecule ligands to selectively deliver drug payloads to diseased cells. It also operates AL102 and related drug candidate AL101. AL102 is an investigational small molecule gamma secretase inhibitor being evaluated in the Phase III for the treatment of desmoid tumors. AL102 is a potential once-daily oral treatment for desmoid tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Immunome, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.75 USD

Average target price

32.5 USD

Spread / Average Target

+106.35%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
IMMUNOME, INC.	+42.90%	944M
REGENERON PHARMACEUTICALS, INC.	+8.88%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-0.83%	104B
ARGENX SE	+5.79%	22.94B
BIONTECH SE	-12.34%	22.34B
GENMAB A/S	-7.01%	19.25B
WUXI APPTEC CO., LTD.	-37.08%	17.08B
BEIGENE, LTD.	-9.25%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+7.61%	14.16B
SAREPTA THERAPEUTICS, INC.	+38.29%	12.63B

Bio Therapeutic Drugs